N末端B型利钠肽原作为预测子痫前期及母胎并发症的生物标志物
这项在西班牙五个中心开展的前瞻性巢式病例对照研究纳入316例疑似子痫前期的单胎孕妇,评估NT-proBNP等标志物预测1周内及4周内子痫前期和胎盘并发症的能力。NT-proBNP最佳阈值为116 pg/mL,预测1周内早发型子痫前期的敏感度90.9%、特异度94.3%,AUC 0.971,与sFlt-1/PlGF比值(AUC 0.970)相近。
要点
- NT-proBNP阈值116 pg/mL预测1周内早发型子痫前期AUC 0.971,与sFlt-1/PlGF比值AUC 0.970相近。
- NT-proBNP预测1周内子痫前期相关并发症AUC 0.818,与sFlt-1/PlGF比值AUC 0.822相近。
- hs-TnT和尿酸对任何类型、早发型及足月子痫前期的预测能力均逊于sFlt-1/PlGF比值。
核心结论
- NT-proBNP阈值116 pg/mL预测评估后1周内早发型子痫前期的诊断性能与sFlt-1/PlGF比值相似,可在临床用于子痫前期的早期识别和管理,尤其适用于无法获得sFlt-1/PlGF比值的情况。
研究设计与样本
- 前瞻性巢式病例对照研究,2018年3月至2020年12月在西班牙五个中心开展,纳入316例孕24+0至41+0周、疑似子痫前期的单胎孕妇,共424份样本,参考标准为子痫前期及胎盘并发症的临床诊断。
诊断标准与关键数值
- NT-proBNP预测1周内早发型子痫前期的最佳阈值为116 pg/mL,敏感度90.9%(95%CI 70.8-98.9%)、特异度94.3%(95%CI 91.2-96.5%)、阳性预测值5.7%(95%CI 3.7-8.7%)、阴性预测值99.9%(95%CI 99.9-100%),AUC 0.971(95%CI 0.942-1.000)。
临床应用与阅片要点
- 作者认为NT-proBNP可在临床用于子痫前期的早期识别和管理,尤其适用于无法获得sFlt-1/PlGF比值的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: A soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio cut-off of 38 is currently considered optimal for ruling out pre-eclampsia (PE); however, implementation of this ratio in clinical practice is limited. N-terminal pro B-type natriuretic peptide (NT-proBNP) is elevated in PE owing to the cardiovascular effects of this disease. This study aimed to identify the predictive performance of NT-proBNP to detect PE and placental complications within 1 week after assessment, and compare it with the predictive performance of the sFlt-1/PlGF ratio. High-sensitivity troponin T (hs-TnT) and uric acid were also evaluated.
METHODS: This was a prospective nested case-control study conducted in five Spanish centers between March 2018 and December 2020, and comprised women with a singleton pregnancy and suspected PE between 24 + 0 and 41 + 0 weeks' gestation. We evaluated the ability of the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid to predict the development of any-onset (at any gestational age), early-onset (before 34 weeks) or term (at or after 37 weeks) PE within 1 week or 4 weeks after assessment. Predictive performance was assessed by estimating negative predictive values, positive predictive values, sensitivity, specificity and areas under the receiver-operating-characteristics curves (AUCs) for these biomarkers, with corresponding 95% CIs. We performed post-hoc exploratory analyses of associations between the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid in women who developed PE, as well as in women who developed complicated PE (PE plus fetal growth restriction, stillbirth or placental abruption) within 1 week and 4 weeks after assessment.
RESULTS: A total of 323 women with suspected PE at or before 41 + 0 weeks were enrolled in the study, of whom seven were lost to follow-up. The final analysis included 316 eligible participants, with 424 samples. The overall incidence of PE was 23.4% (n = 74) and early-onset PE developed in 8.5% (n = 27) of cases. The sFlt-1/PlGF ratio and NT-proBNP exhibited similar abilities to predict early-onset PE within 1 week after assessment (AUC, 0.970 (95% CI, 0.932-1.000) and 0.971 (95% CI, 0.942-1.000), respectively). hs-TnT and uric acid demonstrated inferior predictive capability compared with the sFlt-1/PlGF ratio for the prediction of any-onset PE, early-onset PE and term PE within 1 week and 4 weeks after assessment. The optimal cut-off for NT-proBNP was 116 pg/mL. At this cut-off, NT-proBNP showed a sensitivity of 90.9% (95% CI, 70.8-98.9%) and a specificity of 94.3% (95% CI, 91.2-96.5%), with a positive predictive value of 5.7% (95% CI, 3.7-8.7%) and a negative predictive value of 99.9% (95% CI, 99.9-100%) in predicting early-onset PE within 1 week of assessment, which was comparable with that of the sFlt-1/PlGF ratio. Participants with PE-related complications had higher levels of all biomarkers, but only NT-proBNP showed a similar predictive ability to the sFlt-1/PlGF ratio for complicated PE within 1 week after assessment (AUC, 0.818 (95% CI, 0.706-0.930) vs 0.822 (95% CI, 0.723-0.921), respectively).
CONCLUSION: An NT-proBNP cut-off value of 116 pg/mL has a similar diagnostic performance to that of the sFlt-1/PlGF ratio in predicting the diagnosis of early-onset PE within 1 week after assessment. Thus, NT-proBNP could be used in clinical practice for the early identification and management of PE, particularly in cases for which the sFlt-1/PlGF ratio is not available. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Nan MN, Garrido-Giménez C, Garcia-Osuna Á, et al. N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications. Ultrasound Obstet Gynecol. 2025. PMID: 40088200. doi:10.1002/uog.29202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。